1 Global Gadobutrol (CAS 138071-82-6) Sales Volume Share by Region (2018-2023)
North America has been the dominant market, with its share slightly fluctuating but generally trending downward from 41.11% in 2018 to 38.40% in 2023. Europe has seen a modest increase in its share, starting at 31.79% and reaching 29.51% by 2023, indicating a growing demand or effective market strategies in this region. The Asia Pacific region’s share has shown a slight increase over the years, moving from 22.49% in 2018 to 26.82% in 2023, suggesting a gradual rise in market penetration or consumer preference. Latin America’s share has also increased, albeit marginally, from 2.63% to 2.87%, which could reflect emerging market potential or successful regional marketing efforts.
Table Global Gadobutrol (CAS 138071-82-6) Sales Volume Share by Region (2018-2023)
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
North America | 41.11% | 41.02% | 40.91% | 40.82% | 39.52% | 38.40% |
Europe | 31.79% | 31.62% | 31.50% | 31.43% | 30.10% | 29.51% |
Asia Pacific | 22.49% | 22.46% | 22.47% | 22.35% | 25.09% | 26.82% |
Latin America | 2.63% | 2.74% | 2.84% | 2.93% | 2.86% | 2.87% |
Middle East and Africa | 1.99% | 2.16% | 2.27% | 2.47% | 2.42% | 2.40% |
Total | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
2 Global Gadobutrol (CAS 138071-82-6) Revenue Share by Region (2018-2023)
North America has been the leading region in terms of market revenue share, starting at 41.97% in 2018 and experiencing a slight decrease to 38.65% by 2023. Europe follows as the second-largest market, with its share declining from 32.08% in 2018 to 29.78% in 2023. The Asia Pacific region shows a gradual increase in its market share, beginning at 21.63% in 2018 and rising to 26.56% in 2023, suggesting a growing significance in the global market.
Latin America’s market share has seen a modest increase over the years, starting at 2.48% in 2018 and reaching 2.79% in 2023. The Middle East and Africa, while having the smallest share, also exhibits a slight upward trend, from 1.84% in 2018 to 2.22% in 2023.
Overall, the data indicates a competitive global market with North America and Europe as the primary contributors to the market revenue.
Table Global Gadobutrol (CAS 138071-82-6) Market Revenue Share by Region (2018-2023)
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
North America | 41.97% | 41.76% | 41.58% | 41.42% | 39.86% | 38.65% |
Europe | 32.08% | 31.91% | 31.79% | 31.72% | 30.38% | 29.78% |
Asia Pacific | 21.63% | 21.73% | 21.82% | 21.77% | 24.75% | 26.56% |
Latin America | 2.48% | 2.60% | 2.71% | 2.81% | 2.77% | 2.79% |
Middle East and Africa | 1.84% | 2.00% | 2.11% | 2.29% | 2.24% | 2.22% |
Total | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
3 Global Gadobutrol (CAS 138071-82-6) Import Volume by Region (2018-2023)
In North America Gadobutrol (CAS 138071-82-6) import market, there’s a noticeable upward trend with a slight dip in 2020, starting at 41.6 tons in 2018, peaking at 77.4 tons in 2023. Asia Pacific also shows an overall increase, with a more pronounced rise from 26.2 tons in 2020 to 34.3 tons in 2023. Europe, on the other hand, has a minimal import volume with a significant jump from 0 tons in previous years to 1.8 tons in 2023. Latin America and Middle East and Africa follow a similar pattern of growth, with Latin America starting at 2.7 tons in 2018 and reaching 5.8 tons in 2023, and Middle East and Africa starting at 2.0 tons and ending at 4.8 tons in the same year.
Table Global Gadobutrol (CAS 138071-82-6) Import Volume by Region (2018-2023) (Tons)
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
North America | 41.6 | 51.8 | 47.7 | 53.3 | 67.0 | 77.4 |
Asia Pacific | 22.7 | 28.4 | 26.2 | 29.2 | 30.6 | 34.3 |
Europe | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 | 1.8 |
Latin America | 2.7 | 3.5 | 3.3 | 3.8 | 4.8 | 5.8 |
Middle East and Africa | 2.0 | 2.7 | 2.7 | 3.2 | 4.1 | 4.8 |
Total | 68.9 | 86.3 | 79.8 | 89.6 | 107.8 | 124.1 |
4 Europe Gadobutrol (CAS 138071-82-6) Export Volume (2018-2023)
The export volume of Gadobutrol (CAS 138071-82-6) from Europe has shown a consistent upward trend from 2018 to 2023. Starting at 68.9 tons in 2018, there was a notable increase to 86.3 tons in 2019. The growth continued, albeit at a varying pace, reaching 79.8 tons in 2020, 89.6 tons in 2021, and 105.2 tons in 2022. The most significant surge occurred between 2021 and 2022, and the upward trajectory continued into 2023, where the export volume peaked at 117.4 tons. This steady growth reflects a strong and expanding presence of European Gadobutrol in the global market, potentially driven by increased demand for MRI contrast agents and effective market strategies by European exporters.
Table Europe Gadobutrol (CAS 138071-82-6) Export Volume (2018-2023) (Tons)
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
Europe | 68.9 | 86.3 | 79.8 | 89.6 | 105.2 | 117.4 |
5 Europe Gadobutrol (CAS 138071-82-6) Revenue (M USD) by Country (2018-2023)
Germany has consistently been the leading market, with revenues starting at 30.40 M USD in 2018 and showing a general upward trend to reach 42.22 M USD by 2023. The UK, while significantly smaller in market size, also exhibits growth, from 12.80 M USD in 2018 to 18.19 M USD in 2023. France and Italy follow similar trajectories with gradual increases in revenue. France’s revenue grew from 16.67 M USD in 2018 to 22.93 M USD in 2023, and Italy’s from 19.28 M USD to 27.15 M USD over the same period. Russia’s market is the smallest among the listed countries, yet it still shows a steady increase from 8.94 M USD in 2018 to 11.28 M USD in 2023.
The total revenue for Europe shows a clear growth pattern, starting at 130.33 M USD in 2018 and ending at 182.30 M USD in 2023, which underscores the increasing demand and market penetration of Gadobutrol across the continent. This data reflects a robust market for Gadobutrol in Europe, with all countries showing revenue growth and the total market expanding by over 40% over six years.
Table Europe Gadobutrol (CAS 138071-82-6) Revenue (M USD) by Country (2018-2023)
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
Germany | 30.40 | 35.61 | 31.46 | 33.95 | 37.47 | 42.22 |
UK | 12.80 | 15.14 | 13.35 | 14.65 | 16.17 | 18.19 |
France | 16.67 | 19.54 | 17.26 | 18.62 | 20.41 | 22.93 |
Italy | 19.28 | 22.71 | 20.12 | 21.84 | 24.19 | 27.15 |
Russia | 8.94 | 10.58 | 9.42 | 10.26 | 9.99 | 11.28 |
Others | 42.22 | 49.78 | 44.22 | 47.82 | 54.19 | 60.52 |
Total | 130.33 | 153.36 | 135.84 | 147.15 | 162.42 | 182.30 |
6 Gadobutrol (CAS 138071-82-6) Market Revenue by North America VS Asia Pacific (2018-2023)
6.1 North America Gadobutrol (CAS 138071-82-6) Market Revenue (2018-2023)
In 2018, the North America Gadobutrol (CAS 138071-82-6) market revenue was at 170.51 M USD with a healthy growth rate of 17.72%. However, 2020 saw a substantial drop in revenue to 177.68 M USD, with the growth rate plummeting to -11.48%, indicating a challenging year for the market. The recovery was swift in 2021, with revenue increasing to 192.18 M USD and the growth rate turning positive at 8.16%. The upward trend continued in 2022, reaching 213.08 M USD, with a growth rate of 10.87%. The most recent year, 2023, shows the highest revenue of the period at 236.59 M USD, accompanied by a solid growth rate of 11.04%.
Figure North America Gadobutrol (CAS 138071-82-6) Revenue (M USD) and Growth Rate (2018-2023)
6.2 Asia Pacific Gadobutrol (CAS 138071-82-6) Market Revenue (2018-2023)
In 2019, the Asia Pacific Gadobutrol market had a notable uptick with a revenue of 104.42 M USD and an 18.85% growth rate, suggesting a robust market performance. However, 2020 presented a challenge with a revenue dip to 93.24 M USD and a -10.71% growth rate, indicating a period of contraction. The market showed resilience in 2021 with a slight recovery to 100.99 M USD and an 8.32% growth rate. A substantial surge was observed in 2022, reaching 132.333 M USD with a 31.03% growth rate, likely due to effective market strategies or increased demand. The peak revenue was in 2023 at 162.57 M USD, though the growth rate slowed to 22.85%, suggesting sustained market expansion but at a decelerated pace. These key years underscore the market’s resilience and growth potential in the Asia Pacific region, despite encountering a downturn.
Figure Asia Pacific Gadobutrol (CAS 138071-82-6) Revenue (M USD) and Growth Rate (2018-2023)
6.3 Comparative Analysis of Gadobutrol (CAS 138071-82-6) Revenue and Growth Rate in North America and Asia Pacific
Comparing the Asia Pacific and North America markets for Gadobutrol (CAS 138071-82-6) from 2018 to 2023, several distinctions and similarities emerge. Both regions experienced a decline in 2020, with the Asia Pacific dropping to a growth rate of -10.71% and North America facing a more severe decline at -11.48%. However, both markets demonstrated resilience with subsequent recoveries.
North America’s market revenue was consistently higher than the Asia Pacific’s throughout the years, suggesting a larger market size or greater demand for Gadobutrol in North America. The growth rates in North America were more moderate compared to the Asia Pacific, which showed more volatility, particularly with the sharp increase in 2022.
Both regions are critical to the global Gadobutrol market, with North America exhibiting a more stable growth pattern and the Asia Pacific market demonstrating the potential for high growth following a period of decline. The ability of both regions to recover and continue growth suggests a robust demand for Gadobutrol in these areas.
